WuXi Biologics and Almirall partner to develop dermatological treatments

By Vassia Barba

- Last updated on GMT

(Image: Getty/Kkolosov)
(Image: Getty/Kkolosov)

Related tags Wuxi Wuxi biologics Dermatology Antibody

Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.

Skin-health focused drug developer, Almirall, looks to utilize WuXiBody, a platform designed by WuXi Biologics, in order to identify bispecific antibodies as ‘effective next-generation therapies’ with dermatological indications, Bhushan Hardas, Almirall’s CSO, stated.

Under the agreement, which, according to Hardas, forms ‘a big step forward’ in developing such treatments, WuXi Biologics will receive an upfront payment as well as development, regulatory and commercial milestone payments for each bispecific antibody generated.

Additionally, WuXi Biologics will be entitled to royalties based on global sales achieved by these projects.

Chris Chen, the CEO of WuXi Biologics told us that the collaboration will focus on atopic dermatitis, however researchers 'cannot discard other dermatological diseases' as well.

Antibody-based treatments are 'excellent' for dermatological indications, since they allow targeting of "specifically the right mediator of the disease,"​ the company's CEO explained to us.

According to Chen, the collaborative work will begin in 2020 and will take place at the company's facilities in Shanghai, China.

The WuXiBody platform is designed for the identification of multiple bispecific antibodies, and, according to WuXi Biologics, it enables almost any monoclonal antibody sequence pair to be assembled into the bispecific construct.

Moreover, WuXi Biologics stated that the platform’s structural flexibility makes it convenient to build various formats with different valency, while it has the potential to expedite the drug development process by six to 18 months, as well as to significantly reduce cost-of-goods.

WuXiBody was launched in August 2018, from this time the company has established 12 global drug development partnerships.

The Chinese contract development and manufacturing organization (CDMO) has experienced significant growth during the recent years, with its CEO, previously announcing​ the company’s plans to “gain more market share from the booming biologics outsourcing market.”​

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us